Cargando…

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era

Detalles Bibliográficos
Autores principales:	Kobayashi, T, Kuroda, J, Yokota, I, Tanba, K, Fujino, T, Kuwahara, S, Isa, R, Yamaguchi, J, Kawata, E, Akaogi, T, Uchiyama, H, Kaneko, H, Uoshima, N, Kobayashi, Y, Teramukai, S, Taniwaki, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742628/ https://www.ncbi.nlm.nih.gov/pubmed/26771809 http://dx.doi.org/10.1038/bcj.2015.111

Ejemplares similares

Diffuse large B-cell lymphoma presenting with central pontine myelinolysis: a case report
por: Kawata, Eri, et al.
Publicado: (2015)

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy
por: Mizuno, Yoshimi, et al.
Publicado: (2018)

Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma
por: Tanba, Kazuna, et al.
Publicado: (2018)

Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy
por: Kaneko, Hiroto, et al.
Publicado: (2022)

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
por: Okamoto, Haruya, et al.
Publicado: (2021)

P1127: WATCHFUL WAITING IS AN ACCEPTABLE TREATMENT OPTION FOR PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A RETROSPECTIVE STUDY
por: Mizuhara, K., et al.
Publicado: (2022)

Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission
por: Kaneko, Hiroto, et al.
Publicado: (2015)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
por: Kuwahara-Ota, Saeko, et al.
Publicado: (2018)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
por: Kawaji‐Kanayama, Yuka, et al.
Publicado: (2021)

Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma
por: Matsumura‐Kimoto, Yayoi, et al.
Publicado: (2020)

1st Kyoto Summer Institute
por: Ida, Masakuni, et al.
Publicado: (1978)

Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial
por: Kobayashi, Tsutomu, et al.
Publicado: (2022)

Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study
por: Mizuhara, Kentaro, et al.
Publicado: (2022)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
por: Onishi, Akio, et al.
Publicado: (2023)

Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era
por: Kawajiri, A, et al.
Publicado: (2016)

Development of the Reading Cognitive Test Kyoto (ReaCT Kyoto) for Early Detection of Cognitive Decline in Patients with Hearing Loss
por: Okano, Takayuki, et al.
Publicado: (2020)

High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif
por: Tsukamoto, Taku, et al.
Publicado: (2017)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

Tokyo-Kyoto : Kiki Baron /

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION
por: Ogawa, Takahiro, et al.
Publicado: (2019)

Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016)

The Kyoto Protocol : its development, implication, and the future.
Publicado: (2004)

Clinical outcome of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era
por: Sato, Ai, et al.
Publicado: (2014)

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kang, Jihoon, et al.
Publicado: (2017)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Comparison of endoscopic gastritis based on Kyoto classification between diffuse and intestinal gastric cancer
por: Toyoshima, Osamu, et al.
Publicado: (2021)

Anomaly Busters hit Kyoto
Publicado: (1985)

Anomalie-clastie à Kyoto
Publicado: (1985)

Le Symposium de Kyoto
Publicado: (1985)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab
por: McLaughlin, Christopher, et al.
Publicado: (2022)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
por: Lee, H. J., et al.
Publicado: (2022)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

Kyoto: Polarized protons at high temperature
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_ih10kkmvtec25pode8ijhhpqag